A retrospective evaluation of maternal serum screening for the detection of fetal aneuploidy

Kaoru Suzumori, Mitsuyo Tanemura, Isamu Murakami, Setsuo Okada, Michiya Natori, Mamoru Tanaka, Tsukasa Takagi, Akio Sato

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

A retrospective evaluation of alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and unconjugated oestriol (uE3) levels in maternal blood in the second trimester was conducted for cases of aneuploid pregnancies identified from a series of women who underwent amniocentesis. Blood samples were collected from 1078 women just before genetic amniocentesis was performed, mainly for individuals of advanced maternal age (greater than 35 years). Twenty-five maternal serum samples from pregnant women with an aneuploid fetus, including 14 with Down's syndrome, were available for analysis of all three parameters. An algorithm to detect Down's syndrome was used for this analysis with a risk of ≤ 1:299 classified as screen-positive, this being found for 20.4 per cent of the cases (220/1078). The actual Down's syndrome detection rate was 85.7 per cent (12/14), whereas the detection rate for all aneuploidies was 72.0 per cent (18/25). Those that were not detected were two cases of trisomy 21, one trisomy 18, two trisomy 13, three sex chromosome abnormalities, and one case of an additional marker chromosome. The data indicate that this tri-analyte test should be provided after thorough genetic counselling and informed decision-making regarding maternal serum screening for women who wish for a prenatal diagnosis.

Original languageEnglish
Pages (from-to)861-866
Number of pages6
JournalPrenatal Diagnosis
Volume17
Issue number9
DOIs
Publication statusPublished - 1997 Sept 1

Keywords

  • Aneuploidy
  • Down's syndrome
  • Maternal serum markers
  • Prenatal screening

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'A retrospective evaluation of maternal serum screening for the detection of fetal aneuploidy'. Together they form a unique fingerprint.

Cite this